{"disease":{"id":"chronic-inducible-urticaria","name":"chronic inducible urticaria"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05976243","title":"A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":362,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05405660","title":"A Study of CDX-0159 in Patients With Chronic Inducible Urticaria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":196,"lead_sponsor_name":"Celldex Therapeutics","has_results":false},{"nct_id":"NCT06931405","title":"Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":105,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT06865651","title":"Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":44,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05024058","title":"Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":39,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06050928","title":"Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Escient Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT06603220","title":"A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Evommune, Inc.","has_results":false},{"nct_id":"NCT05960708","title":"A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Yuhan Corporation","has_results":false},{"nct_id":"NCT06353971","title":"A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Jasper Therapeutics, Inc.","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}